Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RISPERDAL CONSTA

« Back to Dashboard

Summary for Tradename: RISPERDAL CONSTA

Patents:12
Applicants:1
NDAs:1
Suppliers: see list1

Clinical Trials for: RISPERDAL CONSTA

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
Status: Completed Condition: Healthy

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
Status: Active, not recruiting Condition: Anorexia Nervosa

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
Status: Completed Condition: Schizophrenia

Bioequivalence Test for Risperdal 2mg of Janssen Korea
Status: Completed Condition: Healthy

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
Status: Completed Condition: Schizophrenia; Psychotic Disorders; Substance Abuse; Alcohol Abuse

An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
Status: Terminated Condition: Schizophrenia

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
Status: Completed Condition: Schizophrenia

Risperdal Consta for Bipolar Disorder
Status: Completed Condition: Bipolar I Disorder

An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
Status: Completed Condition: Schizophrenia

Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
Status: Completed Condition: Schizophrenia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346Oct 29, 2003RXYes6,403,114*PED<disabled>Y<disabled>
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346Oct 29, 2003RXNo7,547,452*PED<disabled>Y<disabled>
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346Oct 29, 2003RXNo6,368,632*PED<disabled>Y<disabled>
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346Oct 29, 2003RXYes6,194,006*PED<disabled>Y<disabled>
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346Oct 29, 2003RXNo5,916,598*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc